Email This Article

FDA Panel Rejects Cephalon's Sparlon
By Robert Steyer
03/23/06 - 07:28 PM EST
The company is dealt a serious blow as experts say the ADHD drug poses too many risks.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,358.52 1,097.39 2,151.60 32.22
Oil *
77.17
DOWN
105.88
DOWN
13.24
DOWN
24.45
DOWN
0.57
10 Yr
3.22%
SPDR Gold
115.23
-1.01%
-1.19%
-1.12%
-1.74%
Data delayed 20 minutes

Brokerage Partners